

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation				l.
1. Given Name (First Name) Jed	2. Surname (Black	Last Name)			3. Date 30-May-2018
4. Are you the corresponding author?	Yes	✓ No	Correspond Paula K. Sc	_	
5. Manuscript Title Solriamfetol for Excessive Sleepiness in 0	Obstructive S	leep Apnea	: A Randomiz	ed Contro	olled Trial
6. Manuscript Identifying Number (if you kno	ow it)				
Section 2. The Work Under Co	nsideration	n for Publ	ication		
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere If yes, please fill out the appropriate info	but not limited st? ✓ Yes	I to grants, o	ata monitoring	j board, stu	udy design, manuscript preparation,
Excess rows can be removed by pressing					,, pressure 7.55 suiter te aud a rem
Name of Institution/Company	Grant		on-Financial Support [?]	Other?	Comments
Jazz Pharmaceuticals					Dr. Black is a part-time employee of Jazz Pharmaceuticals
Jazz Pharmaceuticals			✓		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.
INC Research (now Syneos Health)			V		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.



Name of Institution/Company	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments				
The Curry Rockefeller Group, LLC			✓		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the manuscript for submission.				
Section 3. Relevant financial a	ctivities	outside 1	the submitted	work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below.									
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Jazz Pharmaceuticals				✓	Dr. Black is a shareholder of Jazz Pharmaceuticals plc.				
Section 4. Intellectual Propert	y Pate	nts & Cop	oyrights						
Do you have any patents, whether plann	ed, pendi	ng or issue	d, broadly releva	nt to the	work? Yes 🗸 No				



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Health), non-fina	non-financial support from Jazz Pharmaceuticals, non-financial support from INC Research (now Syneos ancial support from The Curry Rockefeller Group, LLC, during the conduct of the study; other from Jazz, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information	ation							
1. Given Name (First Name) Lawrence P.	2. Surnar Carter	ne (Last Nar	ne)		3. Date 29-May-2018			
4. Are you the corresponding author?	Yes	✓ No	Correspond Paula K. So	_				
5. Manuscript Title Solriamfetol for Excessive Sleepiness in C	Obstructiv	ve Sleep Ap	onea: A Randomiz	ed Contr	olled Trial			
6. Manuscript Identifying Number (if you know it)								
Section 2. The Work Under Co	nsiderat	tion for P	ublication					
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.								
Name of Institution/Company	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments			
Jazz Pharmaceuticals		✓			Lawrence P. Carter is an employee of Jazz Pharmaceuticals			
Jazz Pharmaceuticals			/		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.			
INC Research (now Syneos Health)			V		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.			



Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
The Curry Rockefeller Group, LLC			✓		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the manuscript for submission.			
C. diago								
Section 3. Relevant finance	ial activities	outside	the submitted	work.				
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below.								
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
Jazz Pharmaceuticals				✓	In the course of employment, Dr. Carter has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc.			
					<u> </u>			
Section 4. Intellectual Pro	perty Pate	ents & Cop	pyrights					
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.								
Patent? Per	nding?	d? Licens	red? Royalties?	License	ce? Comments			
	✓							



Section F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
support from INC	s personal fees from Jazz Pharmaceuticals, non-financial support from Jazz Pharmaceuticals, non-financial C Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the tudy; other from Jazz Pharmaceuticals, outside the submitted work. In addition, Dr. Carter has a patent

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	nation								
1. Given Name (First Name) Dan	2. Surnar Chen	ne (Last Nar	ne)		3. Date 29-May-2018				
4. Are you the corresponding author?	Yes	√ No	Correspond Paula K. So	•					
5. Manuscript Title Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea: A Randomized Controlled Trial									
6. Manuscript Identifying Number (if you k	now it)								
Section 2. The Work Under C									
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	eive paymen g but not lim est? ormation b	t or services nited to gran	from a third party ts, data monitoring	g board, st	ent, commercial, private foundation, etc.) for udy design, manuscript preparation, ity press the "ADD" button to add a row.				
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Jazz Pharmaceuticals		✓			Dan Chen is an employee of Jazz Pharmaceuticals				
Jazz Pharmaceuticals			✓		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.				
INC Research (now Syneos Health)			V		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.				



Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
The Curry Rockefeller Group, LLC			√		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the manuscript for submission.		
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No							
of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the port relations st? vst?	instruction onships tha Yes	ns. Use one line fo t were present d	or each er	ntity; add as many lines as you need by		
of compensation) with entities as describle clicking the "Add +" box. You should repare there any relevant conflicts of interest.	bed in the port relations st? vst?	instruction onships tha Yes	ns. Use one line fo t were present d	or each er	ntity; add as many lines as you need by		
of compensation) with entities as described clicking the "Add +" box. You should report Are there any relevant conflicts of interesting the series of the se	bed in the port relationst? ormation b	rinstruction on ships that yes below.	ns. Use one line fo t were present d No Non-Financial	or each er uring the	atity; add as many lines as you need by a 36 months prior to publication.		



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of nations, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
support from IN	personal fees from Jazz Pharmaceuticals, non-financial support from Jazz Pharmaceuticals, non-financial C Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the tudy; other from Jazz Pharmaceuticals, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	nation				
1. Given Name (First Name) Mark	2. Surna Gotfried	me (Last Nar	me)		3. Date 29-May-2018
4. Are you the corresponding author?	Yes	✓ No	Correspond Paula K. So		
5. Manuscript Title Solriamfetol for Excessive Sleepiness in	n Obstructiv	ve Sleep Ap	onea: A Randomiz	ed Contr	olled Trial
6. Manuscript Identifying Number (if you l	(now it)				
Section 2. The Work Under 0					
Did you or your institution at any time recany aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of intellif yes, please fill out the appropriate in	g but not lin rest? formation k	nited to gran	nts, data monitoring	board, st	udy design, manuscript preparation,
Excess rows can be removed by pressi Name of Institution/Company	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments
azz Pharmaceuticals	✓		V		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.
NC Research (now Syneos Health)			/		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.
he Curry Rockefeller Group, LLC			✓		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the manuscript for submission.



Section 3.	Section 3. Relevant financial activities outside the submitted work.								
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below.									
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
GSK, Boehringer-Inge Pharmaceuticals, and		✓				research funding			
GSK, Boehringer-Inge	lheim	honoraria							
Boehringer-Ingelhein	n		✓			speakers bureau			
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No									
Section 5.	Relationships not c	overed	above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?									
Yes, the follo	wing relationships/cond	itions/cir	cumstance	s are present (exp	olain belo	pw):			
✓ No other rela	tionships/conditions/cir	cumstan	ces that pre	esent a potential o	conflict o	finterest			
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.									

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Gotfried reports grants and non-financial support from Jazz Pharmaceuticals, non-financial support from INC Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the conduct of the study; grants from GSK, Boehringer-Ingelheim, Sanofi, Jazz Pharmaceuticals, and Eisai, personal fees from GSK, Boehringer-Ingelheim, personal fees for serving on a speaker's bureau for Boehringer-Ingelheim, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Inform	nation								
1. Given Name (First Name) Yuan	2. Surname ((Last Name)			3. Date 29-May-2018				
4. Are you the corresponding author?	Yes [√ No	Correspond Paula K. So						
5. Manuscript Title Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea: A Randomized Controlled Trial									
6. Manuscript Identifying Number (if you k	now it)								
			_						
Section 2. The Work Under C	onsideratio	n for Publi	cation						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No									
If yes, please fill out the appropriate inf Excess rows can be removed by pressin			ve more thar	one enti	ty press the "ADD" button to add a row.				
Name of Institution/Company	Grant		n-Financial Support	Other?	Comments				
Jazz Pharmaceuticals		✓			Yuan Lu is an employee of Jazz Pharmaceuticals				
Jazz Pharmaceuticals			/		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.				
INC Research (now Syneos Health)			V		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.				



Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
The Curry Rockefeller Group, LLC			V		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the manuscript for submission.		
Section 3. Relevant financial a	ctivities	outside :	the submitted	work.			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest?							
Jazz Pharmaceuticals		Fees	Support :	✓	In the course of employment, Yuan Lu has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc.		
Section 4. Intellectual Property Patents & Copyrights							
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.							
Patent? Pendin	Issue	Licens	Royalties?	License	ce? Comments		



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
support from INC	rsonal fees from Jazz Pharmaceuticals, non-financial support from Jazz Pharmaceuticals, non-financial Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the tudy; other from Jazz Pharmaceuticals, outside the submitted work. In addition, Dr. Lu has a patent

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information								
1. Given Name (First Name) Atul	2. Surnai Malhotra	me (Last Nar a	me)		3. Date 30-May-2018			
4. Are you the corresponding author?	Yes	✓ No	Correspond Paula K. So	_				
5. Manuscript Title Solriamfetol for Excessive Sleepiness	in Obstructiv	ve Sleep Ap	onea: A Randomiz	ed Contr	olled Trial			
6. Manuscript Identifying Number (if you	know it)							
Section 2. The Work Under	Considera	tion for P	ublication					
any aspect of the submitted work (includi statistical analysis, etc.)? Are there any relevant conflicts of inte If yes, please fill out the appropriate in Excess rows can be removed by press	erest? 🕡	Yes pelow. If yo	No		udy design, manuscript preparation, ity press the "ADD" button to add a rov			
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
azz Pharmaceuticals	✓		/		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.			
NC Research (now Syneos Health)			/		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.			
he Curry Rockefeller Group, LLC			✓		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the			



Section 3. Relevant financial a	ctivitie	s outside t	the submitted s	work			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest?							
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
ResMed				✓	philanthropic donation to UC San Diego in support of a sleep center		
American Thoracic Society				✓	former Officer of ATS, reports having relinquished all outside personal income since 2012		
Section 4. Intellectual Property Patents & Copyrights							
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo							
Section 5. Relationships not covered above							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Malhotra reports grants and non-financial support from Jazz Pharmaceuticals, non-financial support from INC Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the conduct of the study; other from ResMed, other from American Thoracic Society, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation						
1. Given Name (First Name) Russell	2. Surna Rosenbe	me (Last Nar erg	me)		3. Date 29-May-2018		
4. Are you the corresponding author?	Yes	✓ No	Correspond Paula K. So	_			
5. Manuscript Title Solriamfetol for Excessive Sleepiness in 0	Obstructiv	ve Sleep Ap	onea: A Randomiz	ed Contr	olled Trial		
6. Manuscript Identifying Number (if you kn	ow it)						
Section 2. The Work Under Co	nsidera	tion for P	ublication				
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.							
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
azz Pharmaceuticals	✓		/		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.		
NC Research (now Syneos Health)			/		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.		
he Curry Rockefeller Group, LLC			✓		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the		



Section 3. Relevant financial a	Section 3. Relevant financial activities outside the submitted work.							
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below.								
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
Jazz Pharmaceuticals, Actelion, Philips Respironics	✓				research funding			
Eisai	✓	\checkmark			research funding, consultancy fees			
Merck	✓	✓			research funding, honoraria, speakers bureau			
Jazz Pharmaceuticals				✓	served as an advisory board member			
Section 4. Intellectual Property Patents & Copyrights								
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V No								
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest								
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.								

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Rosenberg reports grants and non-financial support from Jazz Pharmaceuticals, non-financial support from INC Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the conduct of the study; grants from Jazz Pharmaceuticals, Actelion, Philips Respironics, grants and personal fees from Eisai, grants and personal fees from Merck, other from Jazz Pharmaceuticals, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Inform	ation						
identifying inform							
Given Name (First Name) Paula K.	2. Surname (l Schweitzer	ast Name)		3. Date 29-May-2018			
4. Are you the corresponding author?	✓ Yes	No					
5. Manuscript Title Solriamfetol for Excessive Sleepiness in	Obstructive SI	eep Apnea: A Rar	ıdomized Contr	rolled Trial			
6. Manuscript Identifying Number (if you kn	ow it)						
Section 2. The Work Under Co	onsideration	for Publicatio	n				
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row.							
Excess rows can be removed by pressing Name of Institution/Company	Grant? Per	rsonal Non-Fina ees? Suppo	Other•	Comments			
azz Pharmaceuticals	V			This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.			
NC Research (now Syneos Health)			ı. 🗆	Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.			
he Curry Rockefeller Group, LLC				The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the manuscript for submission.			



Section 3. Relevant financial activities outside the submitted work.								
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below.								
Name of Entity Grant Personal Non-Financial Support Comments Support Comments								
Jazz Pharmaceuticals, Philips Respironics, and NightBalance								
Section 4. Intellectual Property Patents & Copyrights								
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V No								
Section 5. Relationships not covered above								
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
Yes, the following relationships/conditions/circumstances are present (explain below):								
✓ No other relationships/conditions/circumstances that present a potential conflict of interest								
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.								
Section 6. Disclosure Statement								
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.								
Dr. Schweitzer reports grants and non-financial support from Jazz Pharmaceuticals, non-financial support from INC Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the conduct of the study; grants from Jazz Pharmaceuticals, Philips Respironics, and NightBalance, outside the submitted work.								



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Strohl 1



Section 1. Identifying Information								
1. Given Name (First Name) Kingman P.	2. Surna Strohl	me (Last Nar	ne)		3. Date 30-May-2018			
4. Are you the corresponding author?	Yes	✓ No	Correspond Paula K. So	_				
5. Manuscript Title Solriamfetol for Excessive Sleepiness i	n Obstructiv	ve Sleep Ap	onea: A Randomiz	ed Contr	olled Trial			
6. Manuscript Identifying Number (if you	know it)							
Section 2. The Work Under	Considera	tion for P	ublication					
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the submitted work (including statistics).	ng but not linerest?	nited to gran	nts, data monitoring No	g board, st	ent, commercial, private foundation, etc.) foundation, etc.) founds design, manuscript preparation, ity press the "ADD" button to add a row			
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
azz Pharmaceuticals	V		/		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.			
NC Research (now Syneos Health)			/		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.			
he Curry Rockefeller Group, LLC			✓		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the			

Strohl 2



Section 3. Relevant financial a	ctivities outside the	e submitted work.						
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest?								
Name of Entity	Grant? Personal Fees?	Other?	Comments					
Jazz Pharmaceuticals, Inspire Medical Systems	✓		site principal investigator					
Sommetrics, Galvani Bioelectronics			consultancy fees					
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo								
Section 5. Relationships not covered above								
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest								
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.								

Strohl 3

On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Strohl reports grants and non-financial support from Jazz Pharmaceuticals, non-financial support from INC Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the conduct of the study; grants from Jazz Pharmaceuticals, Inspire Medical Systems, personal fees from Sommetrics, Galvani Bioelectronics, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Strohl 4



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation								
1. Given Name (First Name) Hao	2. Surnai Wang	ne (Last Nar	ne)		3. Date 29-May-2018				
4. Are you the corresponding author?	Yes	√ No	-	Corresponding Author's Name Paula K. Schweitzer, PhD					
5. Manuscript Title Solriamfetol for Excessive Sleepiness in (Obstructiv	ve Sleep Ap	onea: A Randomiz	ed Contr	olled Trial				
6. Manuscript Identifying Number (if you kn	ow it)								
Section 2. The Work Under Co	nsidera	tion for P	ublication						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.									
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Jazz Pharmaceuticals		✓			Hao Wang is an employee of Jazz Pharmaceuticals				
Jazz Pharmaceuticals			/		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.				
INC Research (now Syneos Health)			√		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor				



Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
The Curry Rockefeller Group, LLC			✓		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the manuscript for submission.		
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Ves No If yes, please fill out the appropriate information below.							
Name of Entity Jazz Pharmaceuticals	Grant?	Personal Fees?	Non-Financial Support?	Other?	In the course of employment, Dr. Wang has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc.		
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No							



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. In als may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
support from INC	s personal fees from Jazz Pharmaceuticals, non-financial support from Jazz Pharmaceuticals, non-financial C Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the tudy; other from Jazz Pharmaceuticals, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Zammit 1



Section 1. Identifying Inform	ation					
1. Given Name (First Name) Gary K.	2. Surname (Last Name) Zammit			3. Date 29-May-2018		
4. Are you the corresponding author?	Yes ✓ No Corresponding Author's Nam Paula K. Schweitzer, PhD					
5. Manuscript Title Solriamfetol for Excessive Sleepiness in 0	Obstructiv	ve Sleep Ap	onea: A Randomiz	ed Contr	olled Trial	
6. Manuscript Identifying Number (if you know	ow it)					
Section 2. The Work Under Co	nsidera	tion for P	ublication			
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intereal lf yes, please fill out the appropriate information Excess rows can be removed by pressing	but not linst?	nited to gran Yes pelow. If yo	nts, data monitoring	board, st	udy design, manuscript preparation,	
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
azz Pharmaceuticals	✓		/		This study was funded by Jazz Pharmaceuticals. The study protocol was developed by Jazz Pharmaceuticals with input from Kingman P. Strohl.	
NC Research (now Syneos Health)			/		Data were collected by the study investigators, who had confidentiality agreements with the sponsor. Data were analyzed by INC Research (now Syneos Health) with oversight and compensation by the sponsor.	
he Curry Rockefeller Group, LLC			✓		The first manuscript draft was written by Paula K. Schweitzer, PhD, and Kingman P. Strohl, MD, with input from all the authors; subsequent drafts were prepared with the assistance of The Curry Rockefeller Group, LLC, who was paid by the sponsor. All authors made the decision to submit the manuscript for publication and approved the	

Zammit 2



Merck, McNeil, Sanofi-Aventis, Sanofi-

Synthelabo, Sepracor, Takeda Pharmaceuticals, Vela Pharmaceuticals, Wyeth-Ayerst Research

ICMJE Form for Disclosure of Potential Conflicts of Interest

	l					
Section 3.	Relevant financial a	ctivities	outside t	the submitted	work.	
of compensation clicking the "Add Are there any rele) with entities as describ	oed in the ort relationst?	instruction onships tha Yes	ns. Use one line fo	r each en	ial relationships (regardless of amount atity; add as many lines as you need by 2 36 months prior to publication .
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Catalyst, Celgene, Cel Elan, Epix, Eisai, Elmin Forest, Fresca, Galder GlaxoSmithKline, Gile anssen, Jazz Pharma ohnson, King, Merck Health, Neurocrine Bi Neurim, Neurogen, N Organon, Orphan Me Predix, Purdue, Philip Roxane, Saladax, Sand Synthelabo, Schering Medicine, Sepracor, S Takeda, Takeda Pharr	nex, Arena, Aptalis, , Aventis, Balance Berg, Biomarin, BMS, ohalon, CHDI, Edgemont, ada, Evotec, Flamel, Flex, ma, Genentech, Gilead, ad, H. Lundbeck A/S, ceuticals, Johnson & , National Institutes of osciences, Naurex, ovartis, Novo Nordisk, dical, Otsuka, Pfizer, s Respironics, Ritter, ofi-Aventis, SanofiPlough, Sequential unovion, Shire, Somaxon, maceuticals North eva, Thymon, Transcept, Pharma, Ultragenyx,	√				research funding
Eli Lilly, Evotec, Forest Pharmaceuticals, King Ligand, McNeil, Mercl Organon, Pfizer, Purd Aventis, Select Comfo Jomnus, Takeda Phar Vyeth	gelheim, Cephalon, Elan, t, GlaxoSmithKline, Jazz g Pharmaceuticals, k, Neurocrine Biosciences, ue, Renovis, Sanofi- ort, Sepracor, Shire, emaceuticals, Vela, and		V			consultancy fees
Neurocrine Biosciences, King Pharmaceuticals,						honoraria

Zammit 3

1



Section 4.					
Section 4.	Intellectual Property Patents & Copyrights				
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work? Yes V				
Section 5.	Relationships not covered above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?					
✓ Yes, the following relationships/conditions/circumstances are present (explain below):					
No other relationships/conditions/circumstances that present a potential conflict of interest					
Dr. Zammit holds an ownership interest in Clinilabs, Inc., Clinilabs IPA, Inc., Home Sleep and Respiratory Care, and Nationwide Sleep Testing					

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Zammit 4



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Rosenberg reports grants and non-financial support from Jazz Pharmaceuticals, non-financial support from INC Research (now Syneos Health), non-financial support from The Curry Rockefeller Group, LLC, during the conduct of the study; grants from Jazz Pharmaceuticals, Actelion, Philips Respironics, grants and personal fees from Eisai, grants and personal fees from Merck, other from Jazz Pharmaceuticals, outside the submitted work; .Dr. Zammit reports grants and non-financial support from Jazz Pharmaceuticals, non-financial support from INC Research (now Syneos Health), nonfinancial support from The Curry Rockefeller Group, LLC, during the conduct of the study; grants from Abbott, AbbVie, Actelion, Adare, Alder, Alkermes, Ancile, Apnex, Arena, Aptalis, Astellas, Astra-Zeneca, Aventis, Balance Therapeutics, Banyu, Berg, Biomarin, BMS, Catalyst, Celgene, Cephalon, CHDI, Edgemont, Elan, Epix, Eisai, Elminda, Evotec, Flamel, Flex, Forest, Fresca, Galderma, Genentech, Gilead, Glaxo Smith Kline, Gilead, H. Lundbeck A/S, Janssen, Jazz Pharmaceuticals, Johnson & Johnson, King, Merck, National Institutes of Health, Neurim, Neurocrine Biosciences, Naurex, Neurim, Neurogen, Novartis, Novo Nordisk, Organon, Orphan Medical, Otsuka, Pfizer, Predix, Purdue, Philips Respironics, Ritter, Roxane, Saladax, Sanofi-Aventis, Sanofi-Synthelabo, Schering-Plough, Sequential Medicine, Sepracor, Sunovion, Shire, Somaxon, Takeda, Takeda Pharmaceuticals North America, Targacept, Teva, Thymon, Transcept, UCB, US WorldMeds Pharma, Ultragenyx, Predix, Vanda, and Wyeth-Ayerst Research, personal fees from Acorda, Actelion, Alexza, Arena, Aventis, Biovail, Boehringer-Ingelheim, Cephalon, Elan, Eli Lilly, Evotec, Forest, Glaxo Smith Kline, Jazz Pharmaceuticals, King Pharmaceuticals, Ligand, McNeil, Merck, Neurocrine Biosciences, Organon, Pfizer, Purdue, Renovis, Sanofi-Aventis, Select Comfort, Sepracor, Shire, Somnus, Takeda Pharmaceuticals, Vela, and Wyeth, personal fees from Neurocrine Biosciences, King Pharmaceuticals, Merck, McNeil, Sanofi-Aventis, Sanofi-Synthelabo, Sepracor, Takeda Pharmaceuticals, Vela Pharmaceuticals, Wyeth-Ayerst Research, outside the submitted work; and Dr. Zammit holds an ownership interest in Clinilabs, Inc., Clinilabs IPA, Inc., Home Sleep and Respiratory Care, and Nationwide Sleep Testing.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Zammit 5